Awaiting development: Guidance and quality standards

Showing 201 to 210 of 364

Guidance and quality standards awaiting development
Title	Type
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]	Technology appraisal guidance
Obinutuzumab for treating primary membranous nephropathy [ID6751]	Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [ID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]	Technology appraisal guidance
Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]	Technology appraisal guidance
Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]	Technology appraisal guidance
Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance